<?xml version="1.0" encoding="UTF-8"?>
<ref id="B41-jpm-11-00138">
 <label>41.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cam</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Charan</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Welker</surname>
    <given-names>A.M.</given-names>
   </name>
   <name>
    <surname>Dravid</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Studebaker</surname>
    <given-names>A.W.</given-names>
   </name>
   <name>
    <surname>Leonard</surname>
    <given-names>J.R.</given-names>
   </name>
   <name>
    <surname>Pierson</surname>
    <given-names>C.R.</given-names>
   </name>
   <name>
    <surname>Nakano</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Beattie</surname>
    <given-names>C.E.</given-names>
   </name>
   <name>
    <surname>Hwang</surname>
    <given-names>E.I.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>DeltaNp73/ETS2 complex drives glioblastoma pathogenesis-targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma</article-title>
  <source>Neuro-oncology</source>
  <year>2020</year>
  <volume>22</volume>
  <fpage>345</fpage>
  <lpage>356</lpage>
  <pub-id pub-id-type="doi">10.1093/neuonc/noz190</pub-id>
  <?supplied-pmid 31763674?>
  <pub-id pub-id-type="pmid">31763674</pub-id>
 </element-citation>
</ref>
